MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.

LG1 & LG2

Scientists at MediaPharma have discovered two proteins, LG1 and LG2 which possess marked pro-adhesive properties and stimulate angiogenesis through an innovative mechanism, independent of VEGF. In a diabetic mouse hind-limb ischemia model, local administration of these compounds markedly restored blood perfusion in a dose dependent fashion.
Based on these observations, MediaPharma is sought to develop LG1 and LG2 as a therapeutic option for Peripheral Artery Diseases and Non-Healing Wounds.